Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study. Yadav V, Bourdette DN, Bowen JD, Lynch SG, Mattson D, Preiningerova J, Bever CT, Simon J, Goldstein A, Burrows GG, et al. Autoimmune Dis. 2012; 2012:954739. Epub 2012 Apr 05. PMID: 22548151. Abstract CommentRecommendBookmarkWatch